Literature DB >> 33229413

α-Synuclein Aggregates Increase the Conductance of Substantia Nigra Dopamine Neurons, an Effect Partly Reversed by the KATP Channel Inhibitor Glibenclamide.

E Hill1, R Gowers2,3, M J E Richardson2, M J Wall4.   

Abstract

Dopaminergic neurons (DNs) in the substantia nigra pars compacta (SNpc) form an important part of the basal ganglia circuitry, playing key roles in movement initiation and coordination. A hallmark of Parkinson's disease (PD) is the degeneration of these SNpc DNs leading to akinesia, bradykinesia and tremor. There is gathering evidence that oligomeric α-synuclein (α-syn) is one of the major pathologic species in PD, with its deposition in Lewy bodies (LBs) closely correlated with disease progression. However, the precise mechanisms underlying the effects of oligomeric α-syn on DN function have yet to be fully defined. Here, we have combined electrophysiological recording and detailed analysis to characterize the time-dependent effects of α-syn aggregates (consisting of oligomers and possibly small fibrils) on the properties of SNpc DNs. The introduction of α-syn aggregates into single DNs via the patch electrode significantly reduced both the input resistance and the firing rate without changing the membrane potential. These effects occurred after 8-16 min of dialysis but did not occur with the monomeric form of α-syn. The effects of α-syn aggregates could be significantly reduced by preincubation with the ATP-sensitive K+ channel (KATP) inhibitor glibenclamide. These data suggest that accumulation of α-syn aggregates in DNs may chronically activate KATP channels leading to a significant loss of excitability and dopamine release.
Copyright © 2021 Hill et al.

Entities:  

Keywords:  KATP; dopamine; electrophysiology; patch clamp; substantia nigra; α-synuclein

Mesh:

Substances:

Year:  2021        PMID: 33229413      PMCID: PMC7810260          DOI: 10.1523/ENEURO.0330-20.2020

Source DB:  PubMed          Journal:  eNeuro        ISSN: 2373-2822


  44 in total

1.  Dynamic I-V curves are reliable predictors of naturalistic pyramidal-neuron voltage traces.

Authors:  Laurent Badel; Sandrine Lefort; Romain Brette; Carl C H Petersen; Wulfram Gerstner; Magnus J E Richardson
Journal:  J Neurophysiol       Date:  2007-12-05       Impact factor: 2.714

2.  Alpha-synuclein in Lewy bodies.

Authors:  M G Spillantini; M L Schmidt; V M Lee; J Q Trojanowski; R Jakes; M Goedert
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

3.  The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system.

Authors:  A Iwai; E Masliah; M Yoshimoto; N Ge; L Flanagan; H A de Silva; A Kittel; T Saitoh
Journal:  Neuron       Date:  1995-02       Impact factor: 17.173

Review 4.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

5.  Diabetes and the risk of developing Parkinson's disease in Denmark.

Authors:  Eva Schernhammer; Johnni Hansen; Kathrine Rugbjerg; Lene Wermuth; Beate Ritz
Journal:  Diabetes Care       Date:  2011-03-16       Impact factor: 19.112

6.  Experimentally Verified Parameter Sets for Modelling Heterogeneous Neocortical Pyramidal-Cell Populations.

Authors:  Paul M Harrison; Laurent Badel; Mark J Wall; Magnus J E Richardson
Journal:  PLoS Comput Biol       Date:  2015-08-20       Impact factor: 4.475

7.  Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies.

Authors:  Lin Lu; Deng-Lei Fu; Hui-Qin Li; Ai-Ju Liu; Ji-Huang Li; Guo-Qing Zheng
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

8.  Introduction of Tau Oligomers into Cortical Neurons Alters Action Potential Dynamics and Disrupts Synaptic Transmission and Plasticity.

Authors:  Emily Hill; Thomas K Karikari; Kevin G Moffat; Magnus J E Richardson; Mark J Wall
Journal:  eNeuro       Date:  2019-10-15

9.  The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.

Authors:  Anne-Laure Mahul-Mellier; Johannes Burtscher; Niran Maharjan; Laura Weerens; Marie Croisier; Fabien Kuttler; Marion Leleu; Graham W Knott; Hilal A Lashuel
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-19       Impact factor: 11.205

10.  K-ATP channels in dopamine substantia nigra neurons control bursting and novelty-induced exploration.

Authors:  Julia Schiemann; Falk Schlaudraff; Verena Klose; Markus Bingmer; Susumu Seino; Peter J Magill; Kareem A Zaghloul; Gaby Schneider; Birgit Liss; Jochen Roeper
Journal:  Nat Neurosci       Date:  2012-08-19       Impact factor: 24.884

View more
  5 in total

1.  A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson's disease: application to preladenant.

Authors:  Rachel Rose; Emma Mitchell; Piet Van Der Graaf; Daisuke Takaichi; Jun Hosogi; Hugo Geerts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-10-09       Impact factor: 2.410

Review 2.  Pathophysiological Features of Nigral Dopaminergic Neurons in Animal Models of Parkinson's Disease.

Authors:  Ezia Guatteo; Nicola Berretta; Vincenzo Monda; Ada Ledonne; Nicola Biagio Mercuri
Journal:  Int J Mol Sci       Date:  2022-04-19       Impact factor: 6.208

3.  Role of upregulation of the KATP channel subunit SUR1 in dopaminergic neuron degeneration in Parkinson's disease.

Authors:  Min Liu; Cui Liu; Xue Xiao; Shuai-Shuai Han; Ming-Xia Bi; Qian Jiao; Xi Chen; Chun-Ling Yan; Xi-Xun Du; Hong Jiang
Journal:  Aging Cell       Date:  2022-04-20       Impact factor: 11.005

4.  Truncating tau reveals different pathophysiological actions of oligomers in single neurons.

Authors:  Emily Hill; Thomas K Karikari; Juan Lantero-Rodriguez; Henrik Zetterberg; Kaj Blennow; Magnus J Richardson; Mark J Wall
Journal:  Commun Biol       Date:  2021-11-04

Review 5.  Linking α-synuclein-induced synaptopathy and neural network dysfunction in early Parkinson's disease.

Authors:  Aishwarya S Kulkarni; Matthew R Burns; Patrik Brundin; Daniel W Wesson
Journal:  Brain Commun       Date:  2022-06-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.